Vijayaraman Pugazhendhi, Cano Óscar, Koruth Jacob S, Subzposh Faiz A, Nanda Sudip, Pugliese Jessica, Ravi Venkatesh, Naperkowski Angela, Sharma Parikshit S
Geisinger Heart Institute, Geisinger Commonwealth School of Medicine, Wilkes Barre, Pennsylvania, USA.
Hospital Universitari i Politècnic La Fe, Valencia, Spain.
JACC Clin Electrophysiol. 2020 Jun;6(6):649-657. doi: 10.1016/j.jacep.2020.02.010. Epub 2020 May 6.
This study aimed to assess the feasibility and success rates of permanent His-Purkinje conduction system pacing (HPCSP) in patients requiring pacing after transcatheter aortic valve replacement (TAVR).
TAVR is associated with increased risk for atrioventricular block. HPCSP has the potential to reduce electromechanical dyssynchrony associated with right ventricular pacing. The feasibility and safety of HPCSP in this population are unknown.
Consecutive patients requiring pacemakers after TAVR in whom His bundle pacing (HBP) and/or left bundle branch area pacing (LBBAP) was attempted at 5 centers were included in the study. Implant success rates, pacing characteristics, QRS duration, and left ventricular ejection fraction were assessed. Any procedure-related complications, lead revisions, heart failure hospitalizations, and deaths were documented.
HPCSP was successful in 55 of 65 (85%) patients studied. HBP was successful in 29 of 46 patients (63%), and LBBAP was successful in 26 of 28 (93%) patients in whom it was attempted. HBP was more successful in patients with Sapien valves than in those with CoreValves (69% vs. 44%; p < 0.05). LBBAP was associated with lower pacing thresholds and higher R-wave amplitudes at implantation compared with HBP (0.64 ± 0.3 at 0.5 ms vs. 1.4 ± 0.8 at 1 ms; p < 0.001; 14 ± 8 mV vs. 5.5 ± 5.6 mV; p < 0.001). Pacing thresholds remained stable and left ventricular ejection fraction remained unchanged during a mean follow-up of 12 ± 13.7 months.
HPCSP is feasible in the majority of patients requiring pacemakers post-TAVR. Success rates of HBP were lower in patients with CoreValves compared to Sapien valves. LBBAP was associated with higher success rates and lower pacing thresholds compared with HBP.
本研究旨在评估经导管主动脉瓣置换术(TAVR)后需要起搏治疗的患者中,永久性希氏-浦肯野传导系统起搏(HPCSP)的可行性和成功率。
TAVR与房室传导阻滞风险增加相关。HPCSP有可能减少与右心室起搏相关的机电不同步。HPCSP在该人群中的可行性和安全性尚不清楚。
本研究纳入了5个中心连续的TAVR后需要起搏器治疗且尝试进行希氏束起搏(HBP)和/或左束支区域起搏(LBBAP)的患者。评估植入成功率、起搏特征、QRS波时限和左心室射血分数。记录任何与手术相关的并发症、导线修正、心力衰竭住院和死亡情况。
在65例研究患者中,55例(85%)HPCSP成功。HBP在46例患者中有29例成功(63%),LBBAP在28例尝试的患者中有26例成功(93%)。使用Sapien瓣膜的患者HBP成功率高于使用CoreValve瓣膜的患者(69%对44%;p<0.05)。与HBP相比,LBBAP植入时起搏阈值更低,R波振幅更高(0.5毫秒时为0.64±0.3对1毫秒时为1.4±0.8;p<0.001;14±8毫伏对5.5±5.6毫伏;p<0.001)。在平均12±13.7个月的随访期间,起搏阈值保持稳定,左心室射血分数保持不变。
HPCSP在大多数TAVR后需要起搏器治疗的患者中是可行的。与使用Sapien瓣膜的患者相比,使用CoreValve瓣膜的患者HBP成功率较低。与HBP相比,LBBAP成功率更高,起搏阈值更低。